BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases

Next Previous
Trial Profile

BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 24 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top